Company Encyclopedia
View More
name
MircroPort Medbot-B
02252.HK
Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People’s Republic of China. The company offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; SkyWalker, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR’obot, a Mona Lisa robotic transperineal prostate biopsy system. It also offers trans-bronchial surgical robots for trans-bronchial diagnosis and treatment.
127.19 B
02252.HKMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking12/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-118.17%E
    • Profit Margin-143.42%E
    • Gross Margin40.70%B
  • Growth ScoreA
    • Revenue YoY113.92%A
    • Net Profit YoY36.12%B
    • Total Assets YoY36.05%A
    • Net Assets YoY103.08%A
  • Cash ScoreB
    • Cash Flow Margin-69.72%D
    • OCF YoY113.92%A
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreD
    • Gearing Ratio65.74%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MicroPort Medbot 3 directors resigned, nominating 4 persons for non-executive directors and 2 persons for independent directors

    MicroPort Medbot announced that Sun Hongbin resigned from his position as non-executive director and chairman, Fang Cong resigned from his position as executive director, and Li Minghua resigned from his position as independent non-executive director, effective upon the conclusion of the extraordinary general meeting. The company nominated Chang Zhaohua, Bai Tengtaisi, Lu Tian Dianyuu, and Liang Min as non-executive directors, and Zhou Jiahong and Liu Guoen as independent non-executive directors, pending shareholder approval. The three resigning directors confirmed that there were no disagreements with the board of directors

    etnet·
    HK
    02252
    +2.03%
    etnet·
    HK
    02252
    +2.03%

    Morgan Stanley: Raises MicroPort Medbot-W installation forecast, target price increased to HKD 42

    JP Morgan released a research report stating that it has raised the target price for MicroPort Medbot-B from HKD 30.9 to HKD 42, valuing it based on discounted cash flow rates. The investment rating is "Overweight," reaffirming the stock as the top choice among Chinese medical technology stocks, and indicating that the recent price pullback presents a good buying opportunity given that the fundamental factors remain unchanged. MicroPort Medbot's global order momentum remains strong, with over 170 surgical robot orders accumulated as of last Wednesday (the 8th), up from 150 at the end of August. The report noted that the installation of Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with rapid international expansion, applied in nearly 40 countries and major hospital systems, driving strong adoption. The bank has raised its forecast for the number of installations completed this year from 84 to 105, primarily due to growth overseas and the assumption that orders can be converted into sales within less than a quarter, based on approximately 100 cumulative orders for Toumai. There is an expectation of improved installation volume and product mix, as well as an anticipated gross margin improvement of 1 to 1.5 percentage points

    Zhitong·
    HK
    02252
    +2.03%
    Zhitong·
    HK
    02252
    +2.03%

    Understanding the Market | MicroPort Medbot-B rose over 5%, and the commercialization process of TuMai has entered a stage of full acceleration, with overseas orders exceeding 60 units

    MicroPort Medbot-B's stock price rose by more than 5%, reaching HKD 30.2, with a transaction volume of HKD 130 million. According to the announcement, as of now, the order volume for core products in endoscopy, orthopedics, and vascular intervention has exceeded 170 units, among which the global commercialization orders for the Tumai endoscopic surgical robot have surpassed 100 units, and overseas orders have exceeded 60 units, covering nearly 40 countries and regions, accelerating the commercialization process

    Zhitong·
    HK
    02252
    +2.03%
    Zhitong·
    HK
    02252
    +2.03%

    J.P. Morgan Sticks to Its Buy Rating for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)

    According to TipRanks, Choi is a 4-star analyst with an average return of 55.0% and a 100.00% success rate. Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of HK$33.13.

    Tip Ranks·
    HK
    02252
    +2.03%
    Tip Ranks·
    HK
    02252
    +2.03%

    Brief News: MicroPort Medbot sales strong, stock price skyrocketed 2.5 times this year

    Shanghai MicroPort Medical Robotics (Group) Co., Ltd. reported that its core product order volume exceeded 170 units, among which the "TuMai" laparoscopic surgical robot orders surpassed 100 units, with nearly 80 units installed globally, ranking first among domestic brands. This product has entered a comprehensive commercialization stage, with overseas orders exceeding 60 units, covering 40 countries. Although the stock price fell nearly 1% on Thursday, it has increased 2.5 times year-to-date

    BambooWorks·
    HK
    02252
    +2.03%
    BambooWorks·
    HK
    02252
    +2.03%
    © 2025 Longbridge｜Disclaimer